All news

No transactions reported by Spero Therapeutics (SPRO) director William Ho.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Spero Therapeutics Inc.'s recent Form 3 filing identifies William Ho as a new director, reporting zero transactions. The filing, accepted by the SEC on November 10, 2026, also includes a director power-of-attorney exhibit. This indicates that while Mr. Ho has joined the board, he has not yet engaged in any beneficial ownership activities of company securities.

Read original source

SPRO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.